Key result
High-dose cyclophosphamide linked to severe but reversible cardiomyopathy, likely exacerbated by prior mediastinal irradiation.
Case Report (n=1)
Prior mediastinal irradiation may be a risk factor for the development of cyclophosphamide-induced cardiomyopathy.
May warrant cardiac monitoring after high-dose cyclophosphamide in irradiated patients; leaves open prospective confirmation of this association.
A 17-year-old man with mediastinal seminoma was treated with chemotherapy and mediastinal irradiation therapy. Then he received high-dose chemotherapy containing cyclophosphamide (CY) followed by autologous peripheral blood stem cell transplantation. He suffered from CY-induced cardiomyopathy beginning six days after the administration of high-dose CY. The predictable factors associated with the onset of CY-induced cardiomyopathy are not precisely known. It is suggested that the history of mediastinal irradiation was responsible for the onset of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Kamezaki et al. (2005) conducted a case report in Seminoma and Cyclophosphamide-induced Cardiomyopathy (n=1). High-dose cyclophosphamide and mediastinal irradiation was evaluated on Development of cardiomyopathy. A 17-year-old man with mediastinal seminoma developed severe but reversible cyclophosphamide-induced cardiomyopathy six days after high-dose cyclophosphamide, likely exacerbated by prior mediastinal irradiation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: